Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973053 | 0.68 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL1419206 | 0.64 | NQO2 (0.34) | — | |
| SCHEMBL2496995 | 0.64 | NOS1 (0.38) | ALDH1A1GAAUSP2ALOX15NPC1 | |
| SCHEMBL20689261 | 0.64 | TYK2 (0.39) | ALDH1A1GAAUSP2ALOX15NPC1 | |
| SCHEMBL21831808 | 0.62 | KDM4E (0.32) | ALDH1A1NPC1RAB9A | |
| SCHEMBL20688210 | 0.61 | TYK2 (0.49) | ALDH1A1GAAUSP2ALOX15NPC1 | |
| SCHEMBL7622908 | 0.60 | CDK4 (0.35) | — | |
| SCHEMBL9208233 | 0.60 | MAPT (0.50) | ALDH1A1 | |
| SCHEMBL8557822 | 0.60 | BRPF1 (0.50) | ALDH1A1 | |
| SCHEMBL14196470 | 0.59 | ALDH1A1 (0.41) | ALDH1A1GAANPC1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | ALDH1A1 902/4885GAA 119/4885USP2 3644/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | ALDH1A1 902/4885GAA 119/4885USP2 3644/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | ALDH1A1 1059/4885GAA 83/4885USP2 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.